285 related articles for article (PubMed ID: 23224235)
1. Adjuvant therapy with tamoxifen compared to aromatase inhibitors for 257 male breast cancer patients.
Eggemann H; Ignatov A; Smith BJ; Altmann U; von Minckwitz G; Röhl FW; Jahn M; Costa SD
Breast Cancer Res Treat; 2013 Jan; 137(2):465-70. PubMed ID: 23224235
[TBL] [Abstract][Full Text] [Related]
2. Use of tamoxifen with postsurgical irradiation may improve survival in estrogen and progesterone receptor-positive male breast cancer.
Fogh S; Hirsch AE; Langmead JP; Goldberg SI; Rosenberg CL; Taghian AG; Powell SN; Kachnic LA
Clin Breast Cancer; 2011 Mar; 11(1):39-45. PubMed ID: 21421521
[TBL] [Abstract][Full Text] [Related]
3. Optimizing adjuvant endocrine therapy in postmenopausal women with early-stage breast cancer: a decision analysis.
Punglia RS; Kuntz KM; Winer EP; Weeks JC; Burstein HJ
J Clin Oncol; 2005 Aug; 23(22):5178-87. PubMed ID: 15998905
[TBL] [Abstract][Full Text] [Related]
4. Preventing relapse beyond 5 years: the MA.17 extended adjuvant trial.
Goss PE
Semin Oncol; 2006 Apr; 33(2 Suppl 7):S8-12. PubMed ID: 16730271
[TBL] [Abstract][Full Text] [Related]
5. Survival benefit of tamoxifen and aromatase inhibitor in male and female breast cancer.
Eggemann H; Altmann U; Costa SD; Ignatov A
J Cancer Res Clin Oncol; 2018 Feb; 144(2):337-341. PubMed ID: 29098396
[TBL] [Abstract][Full Text] [Related]
6. Is there a role for adjuvant tamoxifen in progesterone receptor-positive breast cancer? An in silico clinical trial.
Hilsenbeck SG; Osborne CK
Clin Cancer Res; 2006 Feb; 12(3 Pt 2):1049s-1055s. PubMed ID: 16467123
[TBL] [Abstract][Full Text] [Related]
7. The impact of tumor progesterone receptor status on optimal adjuvant endocrine therapy for postmenopausal patients with early-stage breast cancer: a decision analysis.
Punglia RS; Kuntz KM; Winer EP; Weeks JC; Burstein HJ
Cancer; 2006 Jun; 106(12):2576-82. PubMed ID: 16703595
[TBL] [Abstract][Full Text] [Related]
8. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer.
; Thürlimann B; Keshaviah A; Coates AS; Mouridsen H; Mauriac L; Forbes JF; Paridaens R; Castiglione-Gertsch M; Gelber RD; Rabaglio M; Smith I; Wardley A; Price KN; Goldhirsch A
N Engl J Med; 2005 Dec; 353(26):2747-57. PubMed ID: 16382061
[TBL] [Abstract][Full Text] [Related]
9. The use of early adjuvant aromatase inhibitor therapy: contributions from the BIG 1-98 letrozole trial.
Forbes JF
Semin Oncol; 2006 Apr; 33(2 Suppl 7):S2-7. PubMed ID: 16730270
[TBL] [Abstract][Full Text] [Related]
10. Identifying breast cancer patients most likely to benefit from aromatase inhibitor therapy after adjuvant radiation and tamoxifen.
Freedman GM; Anderson P; Li T; Ross E; Swaby R; Goldstein L
Cancer; 2006 Dec; 107(11):2552-8. PubMed ID: 17061250
[TBL] [Abstract][Full Text] [Related]
11. Switching to an aromatase inhibitor provides mortality benefit in early breast carcinoma: pooled analysis of 2 consecutive trials.
Boccardo F; Rubagotti A; Aldrighetti D; Buzzi F; Cruciani G; Farris A; Mustacchi G; Porpiglia M; Schieppati G; Sismondi P
Cancer; 2007 Mar; 109(6):1060-7. PubMed ID: 17295293
[TBL] [Abstract][Full Text] [Related]
12. Prognostic factors of early distant recurrence in hormone receptor-positive, postmenopausal breast cancer patients receiving adjuvant tamoxifen therapy: results of a retrospective analysis.
Debled M; MacGrogan G; Brouste V; Mathoulin-Pelissier S; Durand M; Mauriac L
Cancer; 2007 Jun; 109(11):2197-204. PubMed ID: 17450590
[TBL] [Abstract][Full Text] [Related]
13. The role of aromatase inhibitors as adjuvant therapy for early breast cancer in postmenopausal women.
Mouridsen HT; Robert NJ
Eur J Cancer; 2005 Aug; 41(12):1678-89. PubMed ID: 16098456
[TBL] [Abstract][Full Text] [Related]
14. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98.
Coates AS; Keshaviah A; Thürlimann B; Mouridsen H; Mauriac L; Forbes JF; Paridaens R; Castiglione-Gertsch M; Gelber RD; Colleoni M; Láng I; Del Mastro L; Smith I; Chirgwin J; Nogaret JM; Pienkowski T; Wardley A; Jakobsen EH; Price KN; Goldhirsch A
J Clin Oncol; 2007 Feb; 25(5):486-92. PubMed ID: 17200148
[TBL] [Abstract][Full Text] [Related]
15. Contemporary systemic therapy for male breast cancer.
Bradley KL; Tyldesley S; Speers CH; Woods R; Villa D
Clin Breast Cancer; 2014 Feb; 14(1):31-9. PubMed ID: 24220158
[TBL] [Abstract][Full Text] [Related]
16. Update of the BIG 1-98 Trial: where do we stand?
Joerger M; Thürlimann B
Breast; 2009 Oct; 18 Suppl 3():S78-82. PubMed ID: 19914548
[TBL] [Abstract][Full Text] [Related]
17. Tamoxifen versus control after adjuvant, risk-adapted chemotherapy in postmenopausal, receptor-negative patients with breast cancer: a randomized trial (GABG-IV D-93)--the German Adjuvant Breast Cancer Group.
Kaufmann M; Graf E; Jonat W; Eiermann W; Geberth M; Albert US; Gademann G; Conrad B; Stahl K; von Minckwitz G; Schumacher M;
J Clin Oncol; 2005 Nov; 23(31):7842-8. PubMed ID: 16258087
[TBL] [Abstract][Full Text] [Related]
18. Tamoxifen adherence and its relationship to mortality in 116 men with breast cancer.
Xu S; Yang Y; Tao W; Song Y; Chen Y; Ren Y; Liu J; Pang D
Breast Cancer Res Treat; 2012 Nov; 136(2):495-502. PubMed ID: 23065002
[TBL] [Abstract][Full Text] [Related]
19. Aromatase inhibitors versus tamoxifen as adjuvant hormonal therapy for oestrogen sensitive early breast cancer in post-menopausal women: meta-analyses of monotherapy, sequenced therapy and extended therapy.
Josefsson ML; Leinster SJ
Breast; 2010 Apr; 19(2):76-83. PubMed ID: 20096578
[TBL] [Abstract][Full Text] [Related]
20. Risk of early recurrence among postmenopausal women with estrogen receptor-positive early breast cancer treated with adjuvant tamoxifen.
Kennecke H; McArthur H; Olivotto IA; Speers C; Bajdik C; Chia SK; Ellard S; Norris B; Hayes M; Barnett J; Gelmon KA
Cancer; 2008 Apr; 112(7):1437-44. PubMed ID: 18286526
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
